Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

GlobeNewswire - April 30, 2025

Nxera Pharma’s Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia

Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has initiated a Phase 3 registrational program to evaluate the efficacy, safet…

Read Full Article

Your Passport to Global Investments

Ivar recommends Swissquote bank for your international investments. By opening your account through the link below and trading 5 lots or more, you will receive $200 to use on Ivar AI and activate your subscription. Take advantage of this exclusive offer available today!

Swissquote

Offer available for you who have not yet opened your account at Swissquote.
Services available globally except for the following countries: Algeria, Belgium, Canada, China, North Korea, USA, France, Hong Kong, Iran, Iraq, Nigeria, Singapore, Syria, Turkey and Zimbabwe.